A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy

Liu, Qiang; Cai, Zengyu; Jiang, Wenjun; Liu, Jiyong; Tai, Zongguang; Li, Guorui; Gong, Chunai; Gao, Shen; Gao, Yuan

doi:10.1186/s12951-019-0513-z

Cited by 62 publications

(51 citation statements)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that the nano‐PTX‐loaded macrophages had better U87‐tumor‐cell inhibition than nano‐PTX alone. Similarly, macrophages loaded with SN38 NPs, [ 117 ] MSN NPs containing DOX, [ 113 ] rGO containing DOX, [ 118 ] and ironic oxide NPs [ 119 ] all showed excellent anti‐tumor ability against various animal tumor models.…”

Section: Engineering Macrophages For Drug Deliverymentioning

confidence: 99%

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

et al. 2020

View full text Add to dashboard Cite

was that most nanoparticles do not have a sufficiently long blood half-life and cannot realize deep penetration in tumor tissue. Thus, recent progress in the development of strategies for mimicking or modulating cells offers a highly attractive alternative to drug delivery. [10-17] As natural immune cells and antigenpresenting cells, macrophages [18] have a long blood half-life and can specifically bind to tumor tissue. Therefore, applying macrophages in chemical drug delivery would lead to a significant increase in drug accumulation in tumors. Since macrophages can engulf foreign particles in nature, they can directly phagocytose drugs and then deliver drugs to tumors. [19] Thus, live macrophages may serve as drug carriers. To further increase the tumor-targeting ability of macrophages, they can be engineered with targeting ligands. [20] In addition, learning from red blood cell (RBC) membrane coating technology, [21-23] a macrophage cell membrane coating was developed and it resulted in enhanced tumor uptake of drugs. On the other hand, macrophages play an important role in modulating the tumor immune microenvironment. M1 macrophages inhibit tumor growth, while M2 macrophages promote tumor growth. Inhibition of M2 macrophages and repolarization of M2 macrophages to M1 macrophages are common strategies to treat solid tumors. Furthermore, since these macrophages express SIRPα on their surface, their phagocytic activity against CD47-expressing tumor cells is significantly affected by the CD47-SIRPα pathway. Therefore, blocking the CD47-SIRPα pathway can further enhance the anti-tumor efficacy of macrophages. Herein, to elucidate the importance of macrophages in tumor therapy (Figure 1), we will first discuss the role of macrophages in cancer immunotherapy, including the inhibition, depletion, and repolarization of tumor-associated macrophages (TAMs) and the blocking of the CD47-SIRPα pathway to enhance phagocytosis in tumor therapy. Then, based on the tumor targeting of M1 macrophages, we will discuss the applications of macrophages, macrophage-derived exosomes, and macrophage-coated NPs for drug delivery. We will thus offer a comprehensive understanding of functionalizing macrophages for tumor therapy. Macrophages play an important role in cancer development and metastasis. Proinflammatory M1 macrophages can phagocytose tumor cells, while antiinflammatory M2 macrophages such as tumor-associated macrophages (TAMs) promote tumor growth and invasion. Modulating the tumor immune microenvironment through engineering macrophages is efficacious in tumor therapy. M1 macrophages target cancerous cells and, therefore, can be used as drug carriers for tumor therapy. Herein, the strategies to engineer macrophages for cancer immunotherapy, such as inhibition of macrophage recruitment, depletion of TAMs, reprograming of TAMs, and blocking of the CD47-SIRPα pathway, are discussed. Further, the recent advances in drug delivery using M1 macrophages, macrophage-derived exosomes, and macrophage-membrane-coated nanoparticles are ela...

show abstract

Section: Engineering Macrophages For Drug Deliverymentioning

confidence: 99%

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our previous studies [33,34] demonstrated that biomimetic nano-delivery systems mediated by macrophage or functional exosome are useful carriers for delivering chemotherapeutics or genes to tumor sites, via active targeting ability. Recently, cell membrane-based biomimetic NPs have received attention for potential drug delivery applications [35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%

Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Cell membrane-covered drug-delivery nanoplatforms have been garnering attention because of their enhanced biointerfacing capabilities that originate from source cells. In this top-down technique, nanoparticles (NPs) are covered by various membrane coatings, including membranes from specialized cells or hybrid membranes that combine the capacities of different types of cell membranes. Here, hybrid membrane-coated doxorubicin (Dox)-loaded poly(lacticco-glycolic acid) (PLGA) NPs (DPLGA@[RAW-4T1] NPs) were fabricated by fusing membrane components derived from RAW264.7(RAW) and 4T1 cells (4T1). These NPs were used to treat lung metastases originating from breast cancer. This study indicates that the coupling of NPs with a hybrid membrane derived from macrophage and cancer cells has several advantages, such as the tendency to accumulate at sites of inflammation, ability to target specific metastasis, homogenous tumor targeting abilities in vitro, and markedly enhanced multi-target capability in a lung metastasis model in vivo. The DPLGA@[RAW-4T1] NPs exhibited excellent chemotherapeutic potential with approximately 88.9% anti-metastasis efficacy following treatment of breast cancer-derived lung metastases. These NPs were robust and displayed the multi-targeting abilities of hybrid membranes. This study provides a promising biomimetic nanoplatform for effective treatment of breast cancer metastasis.

show abstract

“…This research suggests improved patient survival and high levels of intratumoral immune cell infiltrates [20]. Macrophages, which are circulating cells, are recommended by many studies for the treatment of tumors because the use of monocytes/macrophages provides several advantages compared to MSCs: they can be easily obtained from the patient, easily loaded into therapeutic drugs or nanoparticles, and reinjected into the bloodstream [5,11,21,22]. Additionally, macrophages naturally penetrate tumor tissue due to the fact that tumor-associated macrophages (TAM) are one of the most prominent components of tumor mass (up to 50%) [11,23].…”

Section: Introductionmentioning

confidence: 99%

Biomimetic Gold Nanoshell-Loaded Macrophage for Photothermal Biomedicine

Kang

Lee

Park

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The purpose of this study was to investigate the effect of photothermal treatment (PTT) with gold nanoshell (ANS) using a macrophage-mediated delivery system in a head and neck squamous cell carcinoma (HNSCC) cell line. To achieve this, ANSloaded rat macrophages (ANS-MAs) were prepared via the coculture method with ANS. The human HNSCC (FaDu cell) and macrophage (rat macrophage; NR8383 cell) hybrid spheroid models were generated by the centrifugation method to determine the possibility of using ANS-MAs as a cancer therapy. These ANS-MAs were set into the tumor and macrophage hybrid spheroid model to measure PTT efficacy. Kinetic analysis of the spheroid growth pattern revealed that this PTT process caused a decreasing pattern in the volume of the hybrid model containing ANS-MAs (p < 0:001). Comparison with empty macrophages showed harmony between ANS and laser irradiation for the generation of PTT. An annexin V/dead cell marker assay indicated that the PTT-treated hybrid model induced increasing apoptosis and dead cells. Further studies on the toxicity of ANS-MAs are needed to reveal whether it can be considered biocompatible. In summary, the ANS was prepared with a macrophage as the delivery method and protective carrier. The ANS was successfully localized to the macrophages, and their photoabsorption property was stationary. This strategy showed significant growth inhibition of the tumor and macrophage spheroid model under NIR laser irradiation. In vivo toxicology results suggest that ANS-MA is a promising candidate for a biocompatible strategy to overcome the limitations of fabricated nanomaterials. This ANS-MA delivery and PTT strategy may potentially lead to improvements in the quality of life of patients with HNSCC by providing a biocompatible, minimally invasive modality for cancer treatment.

show abstract

A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy

Cited by 62 publications

References 31 publications

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy

Biomimetic Gold Nanoshell-Loaded Macrophage for Photothermal Biomedicine

Contact Info

Product

Resources

About